logo
Twitter
Discord
Email
logo
Alpha Teknova, Inc.

Alpha Teknova, Inc.

NASDAQ•TKNO
CEO: Mr. Stephen Gunstream
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 2021-06-25
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Contact Information
2451 Bert Dr., Hollister, CA, 95023, United States
831-637-1100
www.teknova.com
Market Cap
$264.90M
P/E (TTM)
-12.3
37.2
Dividend Yield
--
52W High
$10.37
52W Low
$3.94
52W Range
16%
3.2
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 3.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2024

Financial Dashboard

Q2 2025 Data

Revenue

$10.29M+7.00%
4-Quarter Trend

EPS

-$0.07-48.62%
4-Quarter Trend

FCF

$3.90M-230.83%
4-Quarter Trend

2025 Q2 Earnings Highlights

Key Highlights

Six Month Revenue Growth Revenue reached $20.08M USD for six months, marking a 6.2% increase over prior period results.
Gross Profit Margin Expansion Gross profit surged 39.5% to $6.99M USD, driven by manufacturing efficiency gains and higher revenue.
Net Loss Significantly Reduced Net loss narrowed 39.0% to $8.22M USD for the six months ended June 30, 2025 compared to 2024.
Operating Cash Flow Improved Cash used in operating activities improved $3.20M USD, totaling $6.20M USD used for the six months.

Risk Factors

Incurred Operating Losses Incurred $8.35M USD operating loss for six months; future profitability maintenance is not guaranteed by current results.
Potential Stock Price Drop Significant portion of outstanding common stock available for immediate resale, risking substantial price depreciation.
Economic Uncertainty Impact Inflation and interest rate changes create uncertainty, potentially causing customers to reduce or delay product orders.
Supplier Concentration Noted Supplier concentration risk noted; Distributor Supplier A accounted for 29% of inventory purchases for six months.

Outlook

Infrastructure Investment Plans Plan to invest in infrastructure to improve operating efficiency and expand capacity at state-of-the-art facilities.
Focus on Key Growth Segments Focus on generating future revenue growth in molecular diagnostics and synthetic biology segments moving forward.
Credit Facility Compliance Must maintain $8.0M USD minimum cash requirement under the Second Amended Credit Agreement terms through maturity.
Personnel Attraction Strategy Attract, hire, and retain qualified personnel required for ongoing business expansion and operational scaling efforts.

Peer Comparison

Revenue (TTM)

Ironwood Pharmaceuticals, Inc.IRWD
$308.52M
-23.0%
Aurora Cannabis Inc.ACB
$246.70M
+27.3%
Canopy Growth CorporationCGC
$195.95M
-4.8%

Gross Margin (Latest Quarter)

AC Immune SAACIU
100.0%
+2494.6 pp
Ironwood Pharmaceuticals, Inc.IRWD
99.5%
-0.0 pp
SOPHiA GENETICS SASOPH
67.0%
-1.2 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ACIU$345.06M-5.5-49.0%2.6%
IRWD$334.61M-42.32.5%174.6%
SOPH$301.62M-4.1-78.9%35.9%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
+2.4%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention

Research & Insights

Reports
All Years
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 8, 2025|
    Revenue: $10.29M+7.0%
    |
    EPS: $-0.07-48.6%
    Beat
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 9, 2025|
    Revenue: $9.80M+5.4%
    |
    EPS: $-0.09-56.5%
    Beat
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 7, 2025|
    Revenue: $37.75M+2.9%
    |
    EPS: $-0.57+50.9%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 8, 2024|
    Revenue: $9.58M+17.2%
    |
    EPS: $-0.17-50.0%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 13, 2024|
    Revenue: $9.61M-16.6%
    |
    EPS: $-0.13-48.0%
    Beat
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 13, 2024|
    Revenue: $9.29M+1.9%
    |
    EPS: $-0.20-35.5%
    Beat
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 27, 2024|
    Revenue: $36.68M-11.4%
    |
    EPS: $-1.16+31.4%
    Miss
  • Form 10-Q - Q3 2023

    Period End: Sep 30, 2023|Filed: Nov 13, 2023|
    Revenue: $8.17M-23.6%
    |
    EPS: $-0.34-57.5%
    Miss